KOSDAQElectronic Components065510

Huvitz

₩6,330▼ 1.25%2026-11-18 close
Market Cap
₩66.8B
Turnover
₩36,965,960
Volume
5.8K
Shares out.
10.6M
PER
—
PBR
0.7×
EPS
-₩605
Dividend Yield
3.87%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩250 per share · Prices as of the 2026-11-18 close

01

Report overview

Huvitz: Dental growth and profit recovery are the test

Huvitz pairs its eye-care examination and diagnostic equipment business with a new dental push, but filed operating profit fell for three consecutive years through 2025, and the company posted controlling-shareholder net losses in 4Q 2025 and 3Q 2026.

  1. 1

    2025 revenue was KRW 118 billion, above KRW 109.4 billion in 2022, but operating profit fell to KRW 5.55 billion and the operating margin to 4.7%.

  2. 2

    The company moved to a controlling-shareholder net loss of KRW 4.97 billion in 2025, and the cumulative controlling-shareholder net loss over the last four quarters is KRW 6.66 billion.

  3. 3

    Operating profit returned to KRW 2.62 billion in 1Q 2026, then declined in 2Q and 3Q 2026.

  4. 4

    Dental equipment sales began in 4Q 2025, and the company said it expects the business to be reflected more fully in 2026 results.

  5. 5

    Shareholder returns are being strengthened through a stated payout target of 30% or more, a higher year-end dividend, and share cancellation.

02

Business structure

Huvitz is a specialty ophthalmic optics medical device company that sells examination equipment such as auto-refractors and lens processors to optical shops, and diagnostic equipment such as OCT, tonometers and slit lamps to eye clinics.

Based on separate-basis revenue of KRW 102.8 billion in 2022, the optical-shop equipment accounted for 69 percent of sales and ophthalmic diagnostic equipment for 31 percent.

Within optical-shop equipment, lens processors made up 25 percent, auto-refractors 18 percent, reflectors 13 percent and auto lensmeters 6 percent. The company is described as holding the number one share of the domestic auto-refractor market and the number three global share.

Exports account for about 90 percent of sales, mainly to Europe, Russia, the Middle East and Africa. The dental business, which uses Lilivis-branded CAD/CAM and scanning equipment, began generating sales in 4Q 2025.

In November 2026, the company said it would work with Japanese dental trading house Morita to expand digital dental sales in Japan. German and Japanese makers have led overseas ophthalmic equipment markets, and Huvitz positions its price competitiveness and integrated functions as differentiators.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩31.5B₩2.5B8.0%
2025Q4₩27.5B-₩2.1B−7.6%
2026Q1₩29.7B₩2.6B8.8%
2026Q2₩32.5B₩2.1B6.6%
2026Q3₩32.7B₩1.8B5.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩109.4B₩19B₩16.6B17.4%16.1%61.9%
2023₩117.7B₩16.4B₩9.6B13.9%8.7%72.5%
2024₩117.9B₩13.3B₩8.4B11.3%7.2%82.4%
2025₩118B₩5.6B-₩5B4.7%−4.7%100.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On filed results, annual revenue rose from KRW 109.4 billion in 2022 to KRW 117.7 billion in 2023, a 7.6 percent increase, then to KRW 117.9 billion in 2024 and KRW 118 billion in 2025, increases of 0.1 percent each year.

Revenue has risen for three consecutive years from 2023 through 2025, but the gains in 2024 and 2025 were only 0.1 percent. Operating profit fell from KRW 19 billion in 2022 to KRW 16.4 billion in 2023, KRW 13.3 billion in 2024 and KRW 5.55 billion in 2025, a decline for three consecutive years from 2023 through 2025.

The operating margin narrowed from 17.4 percent in 2022 to 13.9 percent, 11.3 percent and 4.7 percent in 2025. Revenue stayed roughly flat while margins compressed sharply. Controlling-shareholder net income turned into a net loss of KRW 4.97 billion in 2025.

The company said its 2025 closing included impairment of goodwill and development costs, a non-cash accounting charge, and some one-off costs arose from restructuring its North American base.

By quarter, 4Q 2025 was the low point, with revenue of KRW 27.5 billion, an operating loss of KRW 2.09 billion and a controlling-shareholder net loss of KRW 9.53 billion.

In 1Q 2026 revenue was KRW 29.7 billion and operating profit KRW 2.62 billion, and revenue rose for three consecutive quarters to KRW 32.7 billion in 3Q 2026. Operating profit then fell in 2Q 2026 to KRW 2.13 billion and in 3Q 2026 to KRW 1.84 billion, down 26.9 percent year on year in 3Q.

Controlling-shareholder results returned to a loss of KRW 2.11 billion in 3Q 2026. The company said consolidated net income in 1Q 2026 rose 40.7 percent year on year.

05

Industry analysis

The ophthalmic equipment market is being driven by aging populations and rising demand for eye care. A 2023 brokerage report described the examination equipment market as growing in the mid-3 percent range in advanced economies and around 7 percent or more in emerging markets.

Per-patient eye care spending was reported to have risen about 96 percent in six years, from 2015 to 2021. On the policy side, the third National Health Screening Master Plan for 2021 to 2025 included fundus examination, which raised expectations for wider OCT demand.

Whether that policy effect converts into equipment sales is a point to track in quarterly results. Advanced-economy makers in the US, Europe and Japan have led this technology-intensive market. Huvitz says its products are competitive with German and Japanese offerings.

The optical-shop examination equipment segment is concentrated among a few makers, and the company's domestic leadership underpins its sales stability. In dental, the company is expanding trade show participation and partnerships in the Middle East, where digital dentistry adoption is growing.

Dental is a newer segment, and whether its equipment earns margins comparable to the core eye-care business has not yet been shown in quarterly results.

Diagnostic equipment is growing while the overall operating margin has been falling, so whether sales growth and profitability improve together is the key point of comparison.

06

Outlook

In its February 2026 disclosure, the company said its 2026 results would enter a recovery phase, with the core eye-care earnings base supported by structural improvement from the dental business. It also expected dental sales to be fully reflected in 2026 results.

In North America, Huvitz closed its Texas unit and reorganized its US base in California to strengthen local sales and marketing and improve access to dealers and partners. In Japan, it plans to use Morita's distribution network and dental clinic relationships to widen its product supply base.

In eye care, it showcased an integrated eye-care portfolio including HBM-1, HTG-1 and HRKT-1 at MIDO 2026 in late January. On shareholder returns, the company disclosed in March 2026 a corporate value-up plan targeting a dividend payout of 30 percent or more of consolidated net income, within distributable profit.

Share cancellation is also under way: 326,136 common shares were cancelled on October 27, 2026, and the revised listing is scheduled for November 16, 2026. Whether the recovery view shows up in quarterly figures is mixed.

Operating profit and controlling-shareholder net income declined after 2Q 2026, and 3Q 2026 returned to a controlling-shareholder net loss. The next points to watch are whether dental sales translate into operating profit and whether the operating margin moves above the 4.7 percent recorded in 2025.

07

Valuation

PER
—
PBR
0.7×
ROE
-6.1%
EPS
-₩605
BPS
₩9,795
Dividend per share
₩250

The share price trades below book value per share, which places it in a discount-to-net-asset zone. Because the last four quarters show net losses, the price-to-earnings ratio is not calculated. With earnings-based multiples unavailable, the valuation debate centers on the pace of profit recovery and asset backing.

The 2025 year-end dividend was raised 25 percent from the prior year, and the company set a target payout of 30 percent or more of consolidated net income within distributable profit.

Cash dividend payout ratios averaged about 20 percent over 2022 to 2024, so the gap between the target and past practice is a point to monitor. Debt-to-equity rose from 61.9 percent in 2022 to 100.9 percent in 2025.

At the end of 2025, total equity was KRW 111.9 billion, of which KRW 105.5 billion belonged to controlling shareholders. Share cancellation reduces the number of listed shares. Unless earnings recover, valuation discussion will remain split between the discount to net assets and the continuation of losses.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Possible contribution from the dental business

The Lilivis dental CAD/CAM line began generating sales in 4Q 2025, and the company expects it to be reflected more fully in 2026 results. In November 2026 it outlined a Japan strategy with Morita to broaden local distribution. Its Middle East exhibition activity also showcased a full dental lineup. Bulls cite this as a second growth axis alongside the core eye-care business.

Stronger shareholder return policy

In its March 2026 value-up plan, the company set a target payout of 30 percent or more of consolidated net income. The 2025 year-end dividend was raised 25 percent even after impairment charges. In October 2026, 326,136 common shares were cancelled. Bulls point to the continued return commitment despite weaker earnings.

Room for margin recovery and diagnostic growth

The operating margin fell from 17.4 percent in 2022 to 4.7 percent in 2025, so bulls see room for improvement if core margins recover. Operating profit returned to KRW 2.62 billion in 1Q 2026, and the company said consolidated net income rose 40.7 percent year on year that quarter. Ophthalmic diagnostic equipment accounted for 31 percent of 2022 sales and is the growing segment.

09

Bear factors

Three years of falling operating profit and margins

Revenue rose only 0.1 percent in both 2024 and 2025, while operating profit declined for three consecutive years through 2025. The 2025 operating profit of KRW 5.55 billion was roughly a third of 2022's KRW 19 billion. The operating margin fell to 4.7 percent.

Cumulative controlling-shareholder net losses over the last four quarters total KRW 6.66 billion, so bears focus on flat sales alongside shrinking margins.

Weakening momentum through 2026

Operating profit reached KRW 2.62 billion in 1Q 2026 but then fell to KRW 2.13 billion in 2Q and KRW 1.84 billion in 3Q. The 3Q figure was down 26.9 percent from a year earlier.

Controlling-shareholder net income fell 69.8 percent quarter on quarter to KRW 1.15 billion in 2Q, and 3Q returned to a KRW 2.11 billion net loss. Bears argue the recovery has not carried through quarterly results.

Overseas dependence and balance-sheet strain

Exports account for about 90 percent of sales, concentrated in Europe, Russia, the Middle East and Africa, which exposes the company to regional risk. The debt-to-equity ratio rose from 61.9 percent in 2022 to 100.9 percent in 2025. The 2025 closing included impairments and North American restructuring costs. Bears view these factors as weighing on both earnings capacity and financial flexibility.

10

Risk factors

Geopolitical and export-dependence risk

With exports at about 90 percent of sales, the company is highly exposed to overseas demand and regional conditions. In its 1Q 2026 report, the company pointed to a continuing geopolitical backdrop. This is one factor behind revenue holding near prior-year levels. Changes in tender activity or customs conditions in key regions could widen swings in sales.

Execution risk in dental

Dental equipment is a new business that began generating sales in 4Q 2025. The company expects a fuller contribution in 2026, yet quarterly operating profit has declined since 2Q 2026. Whether dental equipment can earn margins comparable to the core business remains to be shown.

Bears will look for whether overseas channel expansion in Japan and the Middle East converts into supply contracts.

Impairment and balance-sheet risk

The 2025 closing included impairment of goodwill and development costs. The company describes this as a non-cash accounting charge, but further impairments remain possible if intangible assets fail to generate expected returns. Debt-to-equity was 100.9 percent in 2025, up from 61.9 percent in 2022.

Of KRW 111.9 billion in total equity, KRW 105.5 billion is attributable to controlling shareholders, so continued losses would erode that capital base.

11

What to watch next

  1. November 16, 2026

    Revised listing date after cancellation of 326,136 common shares, bringing listed shares to 10,551,759. The change will alter the share base used for per-share metrics.

  2. March 31, 2027 (statutory filing deadline)

    Filing of the 2026 annual report, which will confirm full-year 2026 revenue, operating profit, controlling-shareholder net income and 4Q results. The key comparison is the operating margin against 4.7 percent in 2025.

  3. March 2027 annual general meeting

    Confirmation of the 2026 year-end dividend, which is fixed through board resolution and shareholder approval. It will show whether the stated payout target of 30 percent or more is reflected in actual dividends.

  4. May 15, 2027 (statutory deadline for the first-quarter report)

    Checkpoint for 1Q 2027 results, to see whether the operating profit decline since 2Q 2026 has stopped and whether dental sales contribute to quarterly profitability.

12

Overall view

Huvitz has maintained revenue near KRW 118 billion, supported by its number one domestic position in examination equipment and growth in ophthalmic diagnostic equipment. Operating profit, however, fell from KRW 19 billion in 2022 to KRW 5.55 billion in 2025, and the operating margin narrowed to 4.7 percent.

The company moved to a controlling-shareholder net loss of KRW 4.97 billion in 2025, and the cumulative controlling-shareholder net loss over the last four quarters is KRW 6.66 billion. Operating profit turned positive in 1Q 2026 but declined in 2Q and 3Q.

The dental business began generating sales in 4Q 2025 and is presented as a new growth axis. On shareholder returns, a payout target of 30 percent or more and share cancellation continue.

Strengths include the dental push and shareholder returns, while weaknesses include margin compression, weaker quarterly momentum, overseas dependence and balance-sheet strain. The next checkpoints are the operating margin in the 2026 annual report, the profit contribution from dental sales, and 1Q 2027 results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. ssl.pstatic.net
  2. hankyung.com
  3. dailyinvest.kr
  4. news.mt.co.kr
  5. dailyinvest.kr
  6. dailyinvest.kr
  7. businesspost.co.kr
  8. etoday.co.kr
  9. etoday.co.kr
  10. etoday.co.kr
  11. topstarnews.net
  12. topstarnews.net
  13. supple.kr
  14. news.nate.com
  15. m.news.nate.com
  16. newspim.com
  17. m.news.nate.com
  18. edaily.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis